{
    "root": "aa85406d-4ca9-4343-88dd-854d393ead3a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "IMFINZI",
    "value": "20250228",
    "ingredients": [
        {
            "name": "DURVALUMAB",
            "code": "28X28X9OKV"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE",
            "code": "X573657P6P"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TREHALOSE DIHYDRATE",
            "code": "7YIN7J07X4"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "imfinzi programmed death-ligand 1 ( pd-l1 ) blocking antibody indicated : \u2022 combination platinum-containing chemotherapy neoadjuvant treatment , followed imfinzi continued single agent adjuvant treatment surgery , treatment adult patients resectable ( tumors \u2265 4 cm and/or node positive ) non-small cell lung cancer ( nsclc ) known epidermal growth factor receptor ( egfr ) mutations anaplastic lymphoma kinase ( alk ) rearrangements . ( 1.1 ) \u2022 single agent , treatment adult patients unresectable , stage iii nsclc whose disease progressed following concurrent platinum-based chemotherapy radiation therapy . ( 1.1 ) \u2022 combination tremelimumab-actl platinum-based chemotherapy , treatment adult patients metastatic nsclc sensitizing egfr mutations alk genomic tumor aberrations . ( 1.1 ) \u2022 single agent , treatment adult patients limited-stage small cell lung cancer ( ls-sclc ) whose disease progressed following concurrent platinum-based chemotherapy radiation therapy . ( 1.2 ) \u2022 combination etoposide either carboplatin cisplatin , first-line treatment adult patients extensive-stage small cell lung cancer ( es-sclc ) . ( 1.2 ) \u2022 combination gemcitabine cisplatin , treatment adult patients locally advanced metastatic biliary tract cancer ( btc ) . ( 1.3 ) \u2022 combination tremelimumab-actl , treatment adult patients unresectable hepatocellular carcinoma ( uhcc ) . ( 1.4 ) \u2022 combination carboplatin paclitaxel followed imfinzi single agent , treatment adult patients primary advanced recurrent endometrial cancer mismatch repair deficient ( dmmr ) determined fda-approved test . ( 1.5 , 2.1 )",
    "contraindications": "\u2022 administer imfinzi intravenous infusion 60 minutes dilution . ( 2.4 ) \u2022 neoadjuvant adjuvant treatment resectable nsclc : weight \u2265 30 kg : neoadjuvant : imfinzi 1,500 mg combination chemotherapy every 3 weeks 4 cycles prior surgery . adjuvant : imfinzi 1,500 mg single agent every 4 weeks 12 cycles surgery . ( 2.2 ) weight < 30 kg neoadjuvant : imfinzi 20 mg/kg every 3 weeks combination chemotherapy 4 cycles prior surgery . adjuvant : 20 mg/kg every 4 weeks single agent 12 cycles surgery . ( 2.2 ) \u2022 unresectable stage iii nsclc , following concurrent platinum-based chemotherapy radiation therapy : \u2218 weight \u2265 30 kg : imfinzi 10 mg/kg every 2 weeks 1,500 mg every 4 weeks . ( 2.2 ) \u2218 weight < 30 kg : imfinzi 10 mg/kg every 2 weeks . ( 2.2 ) \u2022 metastatic nsclc : \u2218 weight \u2265 30 kg : imfinzi 1,500 mg every 3 weeks combination tremelimumab-actl 75 mg platinum-based chemotherapy 4 cycles , administer imfinzi 1,500 mg every 4 weeks single agent histology-based pemetrexed maintenance therapy every 4 weeks , fifth dose tremelimumab-actl 75 mg combination imfinzi dose 6 week 16 . ( 2.2 ) \u2218 weight < 30 kg : imfinzi 20 mg/kg every 3 weeks combination tremelimumab-actl 1 mg/kg platinum-based chemotherapy , administer imfinzi 20 mg/kg every 4 weeks single agent histology-based pemetrexed therapy every 4 weeks , fifth dose tremelimumab-actl 1 mg/kg combination imfinzi dose 6 week 16 . ( 2.2 ) \u2022 ls-sclc , following concurrent platinum-based chemotherapy radiation therapy : \u2218 weight \u2265 30 kg : 1,500 mg every 4 weeks . ( 2.2 ) \u2218 weight < 30 kg : 20 mg/kg every 4 weeks . ( 2.2 ) \u2022 es-sclc : \u2218 weight \u2265 30 kg : etoposide either carboplatin cisplatin , administer imfinzi 1,500 mg every 3 weeks combination chemotherapy , 1,500 mg every 4 weeks single agent . ( 2.2 ) \u2218 weight < 30 kg : etoposide either carboplatin cisplatin , administer imfinzi 20 mg/kg every 3 weeks combination chemotherapy , 10 mg/kg every 2 weeks single agent . ( 2.2 ) \u2022 btc : \u2218 weight \u2265 30 kg : administer imfinzi 1,500 mg every 3 weeks combination chemotherapy , 1,500 mg every 4 weeks single agent . ( 2.2 ) \u2218 weight < 30 kg : administer imfinzi 20 mg/kg every 3 weeks combination chemotherapy , 20 mg/kg every 4 weeks single agent . ( 2.2 ) \u2022 uhcc : \u2218 weight \u2265 30 kg : imfinzi 1,500 mg combination tremelimumab-actl 300 mg single dose cycle 1/day 1 , followed imfinzi single agent every 4 weeks . ( 2.2 ) \u2218 weight < 30 kg : imfinzi 20 mg/kg combination tremelimumab-actl 4 mg/kg single dose cycle 1/day 1 , followed imfinzi single agent every 4 weeks . ( 2.2 ) \u2022 dmmr endometrial cancer : \u2218 weight \u2265 30 kg : imfinzi 1,120 mg combination carboplatin paclitaxel every 3 weeks 6 cycles , followed imfinzi 1,500 mg every 4 weeks single agent . ( 2.1 , 2.2 ) \u2218 weight < 30 kg : imfinzi 15 mg/kg combination carboplatin paclitaxel every 3 weeks 6 cycles , followed imfinzi 20 mg/kg every 4 weeks single agent . ( 2.1 , 2.2 ) \u2022 full prescribing information preparation instructions modifications .",
    "warningsAndPrecautions": "imfinzi ( durvalumab ) injection clear opalescent , colorless slightly yellow solution supplied carton containing one single-dose vial either : \u2022500 mg/10 ml ( 50 mg/ml ) ( ndc 0310-4611-50 ) \u2022120 mg/2.4 ml ( 50 mg/ml ) ( ndc 0310-4500-12 ) store refrigerator 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) original carton protect light . freeze . shake .",
    "adverseReactions": "none .",
    "indications_original": "IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: \u2022 in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors \u2265 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) \u2022 as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) \u2022 in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) \u2022 as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) \u2022 in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) \u2022 in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) \u2022 in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) \u2022 in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 )",
    "contraindications_original": "\u2022 Administer IMFINZI as an intravenous infusion over 60 minutes after dilution. ( 2.4 ) \u2022 Neoadjuvant and Adjuvant Treatment of Resectable NSCLC: o Weight \u2265 30 kg: Neoadjuvant : IMFINZI 1,500 mg in combination with chemotherapy every 3 weeks for up to 4 cycles prior to surgery. Adjuvant : IMFINZI 1,500 mg as a single agent every 4 weeks for up to 12 cycles after surgery. ( 2.2 ) o Weight < 30 kg Neoadjuvant : IMFINZI 20 mg/kg every 3 weeks in combination with chemotherapy for up to 4 cycles prior to surgery. Adjuvant : 20 mg/kg every 4 weeks as a single agent for up to 12 cycles after surgery. ( 2.2 ) \u2022 Unresectable Stage III NSCLC, following concurrent platinum-based chemotherapy and radiation therapy: \u2218 Weight \u2265 30 kg: IMFINZI 10 mg/kg every 2 weeks or 1,500 mg every 4 weeks. ( 2.2 ) \u2218 Weight < 30 kg: IMFINZI 10 mg/kg every 2 weeks. ( 2.2 ) \u2022 Metastatic NSCLC: \u2218 Weight \u2265 30 kg: IMFINZI 1,500 mg every 3 weeks in combination with tremelimumab-actl 75 mg and platinum-based chemotherapy for 4 cycles, and then administer IMFINZI 1,500 mg every 4 weeks as a single agent with histology-based pemetrexed maintenance therapy every 4 weeks, and a fifth dose of tremelimumab-actl 75 mg in combination with IMFINZI dose 6 at week 16. ( 2.2 ) \u2218 Weight < 30 kg: IMFINZI 20 mg/kg every 3 weeks in combination with tremelimumab-actl 1 mg/kg and platinum-based chemotherapy, and then administer IMFINZI 20 mg/kg every 4 weeks as a single agent with histology-based pemetrexed therapy every 4 weeks, and a fifth dose of tremelimumab-actl 1 mg/kg in combination with IMFINZI dose 6 at week 16. ( 2.2 ) \u2022 LS-SCLC, following concurrent platinum-based chemotherapy and radiation therapy: \u2218 Weight \u2265 30 kg: 1,500 mg every 4 weeks. ( 2.2 ) \u2218 Weight < 30 kg: 20 mg/kg every 4 weeks. ( 2.2 ) \u2022 ES-SCLC: \u2218 Weight \u2265 30 kg: With etoposide and either carboplatin or cisplatin, administer IMFINZI 1,500 mg every 3 weeks in combination with chemotherapy, and then 1,500 mg every 4 weeks as a single agent. ( 2.2 ) \u2218 Weight < 30 kg: With etoposide and either carboplatin or cisplatin, administer IMFINZI 20 mg/kg every 3 weeks in combination with chemotherapy, and then 10 mg/kg every 2 weeks as a single agent. ( 2.2 ) \u2022 BTC: \u2218 Weight \u2265 30 kg: administer IMFINZI 1,500 mg every 3 weeks in combination with chemotherapy, and then 1,500 mg every 4 weeks as a single agent. ( 2.2 ) \u2218 Weight < 30 kg: administer IMFINZI 20 mg/kg every 3 weeks in combination with chemotherapy, and then 20 mg/kg every 4 weeks as a single agent. ( 2.2 ) \u2022 uHCC: \u2218 Weight \u2265 30 kg: IMFINZI 1,500 mg in combination with tremelimumab-actl 300 mg as a single dose at Cycle 1/Day 1, followed by IMFINZI as a single agent every 4 weeks. ( 2.2 ) \u2218 Weight < 30 kg: IMFINZI 20 mg/kg in combination with tremelimumab-actl 4 mg/kg as a single dose at Cycle 1/Day 1, followed by IMFINZI as a single agent every 4 weeks. ( 2.2 ) \u2022 dMMR endometrial cancer: \u2218 Weight \u2265 30 kg: IMFINZI 1,120 mg in combination with carboplatin and paclitaxel every 3 weeks for 6 cycles, followed by IMFINZI 1,500 mg every 4 weeks as a single agent. ( 2.1 , 2.2 ) \u2218 Weight < 30 kg: IMFINZI 15 mg/kg in combination with carboplatin and paclitaxel every 3 weeks for 6 cycles, followed by IMFINZI 20 mg/kg every 4 weeks as a single agent. ( 2.1 , 2.2 ) \u2022 See full Prescribing Information for preparation and administration instructions and dosage modifications for adverse reactions.",
    "warningsAndPrecautions_original": "IMFINZI (durvalumab) Injection is a clear to opalescent, colorless to slightly yellow solution supplied in a carton containing one single-dose vial either as:\n                  \n                     \n                        \u2022500 mg/10 mL (50 mg/mL) (NDC 0310-4611-50)\n                     \n                        \u2022120 mg/2.4 mL (50 mg/mL) (NDC 0310-4500-12)\n                  \n                  Store in a refrigerator at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) in original carton to protect from light.\n                  Do not freeze. Do not shake.",
    "adverseReactions_original": "None."
}